LFVN Stock Risk & Deep Value Analysis
LifeVantage Corp
Consumer Defensive • Packaged Foods
DVR Score
out of 10
What You Need to Know About LFVN Stock
We analyzed LifeVantage Corp using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran LFVN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
LFVN Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is continued failure of the digital-first pivot to generate organic revenue growth, exacerbated by ongoing declines in core product sales like the MindBody GLP-1 System. If revenue continues to decline at a rate similar to Q3 FY2026 (-25.2% YoY), the company's annual revenue could fall below $160 million in FY2027, severely impacting profitability and cash flow, despite having no debt.
Risk Matrix
Overall
Aggressive
Financial
Low
Market
Medium
Competitive
High
Execution
High
Regulatory
Medium
Red Flags
- ⚠
Significant YoY revenue decline (-25.2% in Q3 FY2026) and EPS decline (-57.7%) despite strategic pivot initiatives.
- ⚠
Full-year guidance for FY2026 expected at the 'lower end', indicating management's subdued outlook.
- ⚠
Weakness mainly attributed to lower sales of the MindBody GLP-1 System, suggesting product-specific demand issues.
- ⚠
Lack of detailed segment revenue breakdown in recent earnings makes it difficult to assess organic vs. acquired growth.
- ⚠
Reliance on a direct-selling model which faces inherent regulatory and competitive challenges and high churn rates.
Upcoming Risk Events
- 📅
Q4 FY2026 Earnings Miss (Estimated late August 2026): A further decline in revenue and EPS, or significantly reduced FY2027 guidance, indicating persistent operational issues and further eroding investor confidence.
- 📅
Regulatory Scrutiny (Ongoing): Increased regulatory oversight on direct-selling models or health claims for nutrigenomic products could lead to fines, operational restrictions, or reputational damage, impacting revenue by potentially 5-10% in affected segments.
When to Reconsider
- 🚪
Exit if quarterly revenue drops below $40 million for two consecutive quarters, indicating accelerating top-line deterioration.
- 🚪
Sell if management reverses the dividend increase or announces significant share dilution without clear, immediate revenue growth catalysts.
- 🚪
Exit if operating income turns negative for two consecutive quarters, indicating unsustainable operating expenses relative to revenue.
Unlock LFVN Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does LifeVantage Corp (LFVN) Do?
Market Cap
$99.29M
Sector
Consumer Defensive
Industry
Packaged Foods
Employees
232
LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, weight management, pre- and pro-biotics and skin and hair care products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 and Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; LifeVantage Daily Wellness, a dietary supplement to strengthen immune health; LifeVantage Rise AM & Reset PM System that provides the body with the right nutrients; LifeVantage D3+, a dietary supplement that provides vitamin D3 and K2, magnesium, calcium, and other trace minerals to support a balanced immune system, strong bones, and cardiovascular health; PhysIQ Fat Burn to support weight management; PhysIQ Prebiotic is a dietary supplement designed to support the good bacteria in the gut and a healthy microbiome; MindBody GLP-1 System, a dietary supplement that combines two products, MB Core and MB Enhance, which are designed to support weight management and wellness by activating GLP-1 naturally and balancing signals along the gut-brain axis; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. It also provides anti-aging skin care products, such as liquid collagen, facial cleansers, eye cream, moisturizing cream, sunscreen, perfecting lotions, hand creams, as well as shampoos, nourishing conditioners, and scalp serums under the TrueScience brand name. It sells its products through its website and network of independent consultants. LifeVantage Corporation is based in Lehi, Utah.
Visit LifeVantage Corp WebsiteInvestment Thesis
If LifeVantage can effectively execute its digital-first pivot and successfully integrate the LoveBiome acquisition to reverse the current steep revenue declines, achieving sustained organic revenue growth of >5% YoY within the next 12-18 months, then the market could re-rate the stock significantly from its current depressed valuation as a struggling turnaround, potentially reaching a market cap of $500M+ if a viable long-term growth trajectory is established.
Is LFVN Stock Undervalued?
Unlock the full AI analysis for LFVN
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
LFVN Price Targets & Strategy
12-Month Target
$7.50
Bull Case
$12.00
Bear Case
$4.00
Valuation Basis
Target based on 12.5x estimated FY2027 EPS of $0.60, reflecting depressed growth prospects in direct selling.
Entry Strategy
Cautious entry on confirmed stabilization. Consider accumulation below $6.00 if fundamental improvements (positive organic revenue growth) are observed. Currently, no compelling technical entry point given the negative momentum.
Exit Strategy
Take profit above $10.00 if a significant positive catalyst emerges. Implement a stop-loss at $5.00, below the current 52-week lows, to protect against further revenue declines and market capitulation.
Portfolio Allocation
0.5% for aggressive risk tolerance only. This is a highly speculative turnaround play with significant headwinds.
Price Targets & Strategy
Sign up free to unlock price targets and entry/exit strategies
Is LFVN Financially Healthy?
Valuation
P/E Ratio
17.26
Forward P/E
9.61
EV/EBITDA
8.18
Price/Sales
0.26
Profitability
Gross Margin
78.14%
Operating Margin
3.37%
Net Margin
2.94%
Return on Equity
17.15%
Revenue Growth
-12.15%
EPS
$0.45
Balance Sheet
Current Ratio
1.87
Quick Ratio
0.89
Cash & Equivalents
$12.50M
Cash Flow
EBITDA
$3.20M
Other
Beta (Volatility)
0.76
Dividend Yield
2.54%
Does LFVN Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
2 Identified
The direct-selling model for supplements is highly susceptible to competition and changing consumer preferences. While LifeVantage has some proprietary formulations, these are not truly unique in a competitive market, and the brand lacks widespread recognition to create significant pricing power or switching costs. The digital pivot is an attempt to address this, but its success is unproven.
Moat Erosion Risks
- •Intense competition from larger CPG companies and online retailers offering similar or superior products.
- •Ease of entry for new direct-selling competitors leveraging digital platforms with more modern approaches.
- •Erosion of distributor base due to declining product sales and perceived lack of income opportunity.
LFVN Competitive Moat Analysis
Sign up to see competitive advantages
LFVN Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to Bearish, given recent poor earnings and lack of visible catalysts for a turnaround.
Institutional Sentiment
Negative, evidenced by the EPS and revenue misses against consensus and likely downward revisions by analysts, though specific ratings are not provided in the research.
Insider Activity (Form 4)
No verifiable insider buy/sell activity (Form 4 filings) was found in the provided research for the last 90 days. Therefore, 'Normal insider activity' is assumed.
Options Flow
Normal options activity; no unusual options flow indicating significant institutional positioning was identified in the provided research.
Earnings Intelligence
Next Earnings
Estimated late August 2026 (for Q4 FY2026)
Surprise Probability
Low, given the recent misses and conservative guidance. The market will likely be cautious.
Historical Earnings Pattern
Based on recent Q3 2026 results (miss on revenue and EPS, stock likely reacted negatively), LFVN stock tends to be highly sensitive to earnings performance, with negative reactions to misses and guidance revisions.
Key Metrics to Watch
Competitive Position
Top Competitor
Herbalife Nutrition (HLF) or USANA Health Sciences (USNA)
Market Share Trend
Losing ground, as indicated by the sharp 25.2% YoY revenue decline in Q3 FY2026. The LoveBiome acquisition only partially offset this, implying organic market share erosion.
Valuation vs Peers
At a P/E of 19.59, LFVN trades at a similar or slightly discounted multiple to some established direct-selling health companies, but this valuation is less attractive given its current revenue decline vs. stable or slow-growing peers. Its small market cap makes it inherently higher risk.
Competitive Advantages
- •Proprietary nutrigenomic formulations (IP/Intangible Assets)
- •Established direct-selling distribution network (albeit facing challenges)
- •Cash on hand with no debt (balance sheet strength)
Market Intelligence
Sign up free to unlock sentiment, earnings intel, and peer analysis
What Could Drive LFVN Stock Higher?
Near-Term (0-6 months)
- •Q4 FY2026 Earnings (Estimated late August 2026): If revenue shows sequential improvement or management provides clear, actionable steps for organic growth and positive FY2027 guidance above current consensus of $0.65 EPS.
- •New Product Launches/Marketing Campaigns (Q3-Q4 2026): Introduction of a new flagship product or successful digital marketing campaign (e.g., targeted influencer partnerships) that significantly reverses the decline in core product sales (e.g., MindBody GLP-1 System).
Medium-Term (6-18 months)
- •LoveBiome Acquisition Integration Success (H1 FY2027): If LoveBiome-related revenue contribution significantly exceeds current partial offset, demonstrating successful cross-selling and expanded distributor network leading to >10% organic revenue growth.
- •Digital Transformation Impact (H1 FY2027): Evidence that the digital-first pivot is effectively attracting and retaining new distributors and customers, resulting in sustained positive customer acquisition cost (CAC) and lifetime value (LTV) trends, driving a return to positive overall revenue growth (e.g., +5% YoY in Q1/Q2 FY2027).
Long-Term (18+ months)
- •Nutrigenomics Market Leadership (FY2028-2029): If LifeVantage establishes a clear market leadership position in a niche segment of the nutrigenomics market, leveraging proprietary science and a highly effective digital direct-selling model, achieving an annual revenue run-rate exceeding $300 million with sustained operating margins above 10%, potentially leading to a higher market multiple.
- •Strategic Partnership/Acquisition (FY2028-2029): A major strategic partnership with a large health & wellness brand or the acquisition of a complementary, high-growth nutraceutical company that significantly expands its product portfolio and market reach, generating an additional $50M+ in annual revenue.
Catalysts & Growth Drivers
Sign up free to see growth catalysts
What's the Bull Case for LFVN?
- ✓
Watch for positive organic revenue growth in subsequent quarterly reports (Q4 FY2026 and Q1 FY2027) as a primary indicator of pivot success.
- ✓
Monitor gross margin stability (current 79.0%) and operating income expansion as signs of operational efficiency.
- ✓
Track distributor count and sales force productivity, if disclosed, to assess the health of the direct-selling model.
Bull Case Analysis
Sign up free to see the bull case
Competing with LFVN
See how LifeVantage Corp compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
LifeVantage Corp LFVN | $99.3M | 2.8 | 17.3 | $43.7M | 2.9% | -12.2% | |
Costco Wholesale Corp COST | — | 0.7 | — | — | — | — | Compare → |
Coca-Cola Co KO | $339.2B | 0.5 | 24.8 | $48.9B | 27.8% | 5.1% | Compare → |
PepsiCo Inc PEP | — | 0.1 | — | — | — | — | Compare → |
Procter & Gamble Co PG | $341.2B | 0.2 | 20.5 | $84.3B | 19.2% | 3.3% | Compare → |
Walmart Inc WMT | $972.0B | 0.7 | 42.8 | $713.2B | 3.1% | 5.9% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How LifeVantage Corp Makes Money
LifeVantage Corp. develops, markets, and sells nutrigenomic dietary supplements, skin and hair care products, and energy drinks. The company primarily uses a direct-selling network of independent distributors to reach customers globally. Distributors earn commissions on product sales and by recruiting new distributors, while customers purchase products directly from distributors or the company's e-commerce platform. The business model relies heavily on distributor engagement, product efficacy, and direct-to-consumer digital outreach to drive sales in the health and wellness market.
Read Full Business Model BreakdownFAQ
What is the DVR Score for LifeVantage Corp (LFVN)?
As of June 2, 2026, LifeVantage Corp has a DVR Score of 2.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of LifeVantage Corp?
LifeVantage Corp's market capitalization is approximately $99.3M. The company operates in the Consumer Defensive sector within the Packaged Foods industry.
What ticker symbol does LifeVantage Corp use?
LFVN is the ticker symbol for LifeVantage Corp. The company trades on the NCM.
What is the risk level for LFVN stock?
Our analysis rates LifeVantage Corp's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of LFVN?
LifeVantage Corp currently has a price-to-earnings (P/E) ratio of 17.3. This is in line with broader market averages.
Does LifeVantage Corp pay a dividend?
Yes, LifeVantage Corp pays a dividend with a current yield of approximately 2.54%.
Is LifeVantage Corp's revenue growing?
LifeVantage Corp has reported revenue growth of -12.2%. Revenue has been declining, which warrants closer examination.
Is LFVN stock profitable?
LifeVantage Corp has a profit margin of 2.9%. The company is profitable but margins are modest.
How often is the LFVN DVR analysis updated?
Our AI-powered analysis of LifeVantage Corp is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on June 2, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for LFVN (LifeVantage Corp) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.